PYPD · PolyPid Ltd. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
PolyPid said Deeplex 100 faces a November 28, 2026 PDUFA date, with U.S. launch expected in 2027 if approved. Its Azurdi Pharmaceuticals partnership received $30 million upfront and offers over $290 million in milestones.
PolyPid introduced PD01B, a Kynatrix-based doxycycline candidate for diabetic foot infections, targeting a pre-IND meeting and first-in-human study in the second half of 2027. D-PLEX₁₀₀ is under FDA Priority Review with a November 28, 2026 PDUFA goal date.
PolyPid’s D-PLEX₁₀₀ marketing authorization application was validated by the European Medicines Agency, initiating formal review. Its FDA Priority Review has a November 28, 2026 PDUFA goal date, and Phase 3 SHIELD II showed a 60% relative risk reduction (p=0.0013).
PolyPid and ADVANZ PHARMA mutually terminated their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe; exclusive European commercialization rights have reverted to PolyPid.
PolyPid Ltd reported a November 28th PDUFA date, pivotal 1,000-patient results of 18% to 10.9%, and an Azuriti Pharmaceutical deal providing $30 million upfront and near-term milestones, with sales planned for 2027.